Product Overview
The NFκB Responsive Luciferase Reporter MCF-7 Stable Cell Line is derived from human breast adenocarcinoma cells and stably expresses a firefly luciferase reporter gene under the control of an NFκB response element. This stable cell line enables sensitive, high-throughput, and quantitative monitoring of NFκB transcriptional regulation and pathway dynamics.
The Advantage: Eliminate Complex Lab Optimization
Like many breast cancer models, MCF-7 cells are notoriously difficult and inefficient to transfect using standard chemical methods. Achieving a stable, high-expressing reporter clone often involves weeks of resource-intensive selection and frustrating optimization. Signosis bypasses this hurdle by utilizing a high-efficiency lentiviral transduction platform to ensure stable, robust reporter integration. This ready-to-use line saves valuable lab time, delivering reproducible results right out of the box.
Biological Relevance
MCF-7 is a cornerstone, estrogen receptor-positive ER+ human breast cancer model widely utilized in cancer biology and endocrinology research. In breast cancer, the NFκB pathway serves as a primary driver of tumor proliferation, cell survival, and the development of resistance to anti-estrogen therapies (such as tamoxifen). This reporter line provides a reliable platform for studying the cross-talk between hormone signaling and inflammatory pathways.
Mechanism of Action
NFκB is a key transcription factor involved in the regulation of immune and inflammatory responses, cell proliferation, differentiation, survival, and apoptosis. In response to stimuli such as cytokines, oxidative stress, and environmental factors, NFκB becomes activated and translocates from the cytoplasm to the nucleus. There, it binds to specific response elements and regulates downstream gene expression. Dysregulation of NFκB signaling is deeply tied to cancer progression and inflammatory disorders, making it a high-value drug target.
Validation and Applications
Signosis established this stable cell line through lentiviral transduction using an NFκB-responsive luciferase reporter construct. Clones were validated based on robust, reproducible TNFα-induced luciferase signaling to ensure exceptional sensitivity. This cell line is ideal for:
Quantifying NFκB signaling dynamics in a breast cancer background.
Screening therapeutic compounds and anti-inflammatory drugs.
Functional profiling of the pathway via gene overexpression or RNA interference (RNAi).
